特发性血小板增多症合并急性心肌梗死1例-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

特发性血小板增多症合并急性心肌梗死1例

Essential thrombocythemia complicated with acute myocardial infarction: a case report

ES评分 0 浏览量：55 下载量：0

DOI	10.12208/j.ijcr.20250004
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(1)
作者	许佳敏¹,胡家新²*,
作者单位	¹南京大学医学院附属南京鼓楼医院心血管内科江苏南京,²武汉大学恩施临床学院恩施土家族苗族自治州中心医院内科心血管疾病中心湖北恩施
摘要	特发性血小板增多症（essential thrombocythemia, ET）是一种慢性骨髓增生性肿瘤，总体表现为不同形态学成熟度和造血效能的髓系细胞克隆性增生，特征为克隆性血小板过度生成，伴血栓形成和出血倾向。ET患者并发症和死亡的主要原因是血栓形成，包括静脉血栓形成（如深静脉血栓形成），以及动脉血栓形成（如脑血管事件、心肌梗死）。本文介绍了1例ET相关的急性心肌梗死的诊断和治疗过程。
Abstract	Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by the clonal proliferation of myeloid cells with varying degrees of maturation and hematopoietic efficiency, featuring the overproduction of clonal platelets, along with a propensity for thrombosis and bleeding. The leading cause of complications and mortality in ET patients is thrombosis, including venous thrombosis (such as deep vein thrombosis) and arterial thrombosis (such as cerebrovascular events, myocardial infarction). This article presents the diagnostic and therapeutic process of a case of acute myocardial infarction associated with ET.
关键词	特发性血小板增多症；心肌梗死；血栓形成
KeyWord	Essential thrombocythemia; Myocardial infarction; Thrombosis
基金项目
页码	11-14

参考文献
相关文献

[1] Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
[2] Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122:3787-3797.
[3] Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22-28.
[4] Gao W, Shen W, Luo X, Shi H, Jiang X, Pan J. ST-segment elevation myocardial infarction in patient with essential thrombocythemia without associated risk. Int J Cardiol. 2015;180:223-225.
[5] Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8:2.
[6] Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med. 1998;244:49-53.
[7] Tortorella G, Calzolari M, Tieghi A, Muia N, Piccin A, Gugliotta L. Acute coronary syndrome (ACS) in patients with essential thrombocytemia (ET). What is the best treatment? Int J Cardiol. 2016;203:225-227.
[8] Hernandez-Boluda JC, Alvarez-Larran A, Gomez M, Angona A, Amat P, Bellosillo B, Martinez-Aviles L, Navarro B, Teruel A, Martinez-Ruiz F, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2011;152:81-88.

引用本文

许佳敏,胡家新*. 特发性血小板增多症合并急性心肌梗死1例 [J]. 国际临床研究杂志. 2025; 9; (1). 11 - 14.

文献评论

相关学者

相关机构